246 related articles for article (PubMed ID: 19472652)
1. Evaluation of the dose distribution for prostate implants using various 125I and 103Pd sources.
Meigooni AS; Luerman CM; Sowards KT
Med Phys; 2009 Apr; 36(4):1452-8. PubMed ID: 19472652
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations.
Li XA; Wang JZ; Stewart RD; DiBiase SJ
Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099
[TBL] [Abstract][Full Text] [Related]
4. The effect of seed anisotrophy on brachytherapy dose distributions using 125I and 103Pd.
Lindsay P; Battista J; Van Dyk J
Med Phys; 2001 Mar; 28(3):336-45. PubMed ID: 11318315
[TBL] [Abstract][Full Text] [Related]
5. Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code.
Bohm TD; DeLuca PM; DeWerd LA
Med Phys; 2003 Apr; 30(4):701-11. PubMed ID: 12722822
[TBL] [Abstract][Full Text] [Related]
6. Some treatment planning considerations for 103Pd and 125I permanent interstitial implants.
Nath R; Meigooni AS; Melillo A
Int J Radiat Oncol Biol Phys; 1992; 22(5):1131-8. PubMed ID: 1555965
[TBL] [Abstract][Full Text] [Related]
7. Isotope choice and the effect of edema on prostate brachytherapy dosimetry.
Butler WM; Merrick GS; Dorsey AT; Lief JH
Med Phys; 2000 May; 27(5):1067-75. PubMed ID: 10841411
[TBL] [Abstract][Full Text] [Related]
8. Relationship between isotope half-life and prostatic edema for optimal prostate dose coverage in permanent seed implants.
Villeneuve M; Leclerc G; Lessard E; Pouliot J; Beaulieu L
Med Phys; 2008 May; 35(5):1970-7. PubMed ID: 18561673
[TBL] [Abstract][Full Text] [Related]
9. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants--a bio-mathematical model.
Yue N; Chen Z; Nath R
Phys Med Biol; 2002 Apr; 47(7):1185-204. PubMed ID: 11996063
[TBL] [Abstract][Full Text] [Related]
10. The impact of edema on planning 125I and 103Pd prostate implants.
Yue N; Dicker AP; Nath R; Waterman FM
Med Phys; 1999 May; 26(5):763-7. PubMed ID: 10360539
[TBL] [Abstract][Full Text] [Related]
11. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
[TBL] [Abstract][Full Text] [Related]
12. Treatment planning consideration for prostate implants with the new linear RadioCoil 103Pd brachytherapy source.
Meigooni AS; Awan SB; Rachabatthula V; Koona RA
J Appl Clin Med Phys; 2005; 6(3):23-36. PubMed ID: 16143789
[TBL] [Abstract][Full Text] [Related]
13. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
Thomson RM; Rogers DW
Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
[TBL] [Abstract][Full Text] [Related]
14. Prescription dose in permanent (131)Cs seed prostate implants.
Yue N; Heron DE; Komanduri K; Huq MS
Med Phys; 2005 Aug; 32(8):2496-502. PubMed ID: 16193779
[TBL] [Abstract][Full Text] [Related]
15. Determination of the prescription dose for biradionuclide permanent prostate brachytherapy.
Nuttens VE; Lucas S
Med Phys; 2008 Dec; 35(12):5451-62. PubMed ID: 19175105
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of low energy brachytherapy Monte Carlo dose calculations to uncertainties in human tissue composition.
Landry G; Reniers B; Murrer L; Lutgens L; Gurp EB; Pignol JP; Keller B; Beaulieu L; Verhaegen F
Med Phys; 2010 Oct; 37(10):5188-98. PubMed ID: 21089752
[TBL] [Abstract][Full Text] [Related]
17. An experimental palladium-103 seed (OptiSeedexp) in a biocompatible polymer without a gold marker: characterization of dosimetric parameters including the interseed effect.
Abboud F; Scalliet P; Vynckier S
Med Phys; 2008 Dec; 35(12):5841-50. PubMed ID: 19175140
[TBL] [Abstract][Full Text] [Related]
18. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
[TBL] [Abstract][Full Text] [Related]
19. A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of prostate.
Yue N; Dicker AP; Corn BW; Nath R; Waterman FM
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):447-54. PubMed ID: 10030274
[TBL] [Abstract][Full Text] [Related]
20. A radiobiological investigation on dose and dose rate for permanent implant brachytherapy of breast using 125I or 103Pd sources.
Baltas D; Lymperopoulou G; Löffler E; Mavroidis P
Med Phys; 2010 Jun; 37(6):2572-86. PubMed ID: 20632569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
